medicina60巻2号

2023年02月発行

特集 慢性疾患診療のお悩みポイントまとめました—高血圧からヘルスメンテナンスまで 骨粗鬆症

ビスホスホネート製剤は5年以上続けるべきですか？

著者： 佐藤直行¹

所属機関： ¹ハートライフ病院総合内科

ページ範囲：P.386 - P.390

Point
◎閉経後骨粗鬆症において，骨密度を主体としたgoal-directed treatmentが提唱されており，治療薬選択の一助となる．
◎ビスホスホネート製剤は使用後5年以内であれば，非定型大腿骨骨折リスクよりも脆弱性骨折リスク低減効果のほうが明らかに有益である．
◎ビスホスホネート製剤を5年以上使用することもできるが，継続するかdrug holidayを設けるかどうかは患者ごとのリスクに応じて検討する．
◎drug holidayの期間はビスホスホネート製剤の各薬剤で異なるが，休薬中も評価は繰り返す必要がある．

参考文献

1）Tai TW, et al：Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality；A nationwide population study. Bone 154：116216, 2022

2）Black DM, et al：Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction；Meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8：672-682, 2020

3）Cummings SR, et al：Goal-directed treatment for osteoporosis；A progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 32：3-10, 2017

4）Cosman F, et al：Romosozumab followed by antiresorptive treatment increases the probability of achieving bone mineral density treatment goals. JBMR Plus 5：e10546, 2021

5）Camacho PM, et al：American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract 26：1-46, 2020

6）Gregson CL, et al：UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17：58, 2022

7）Lippuner K：The future of osteoporosis treatment；A research update. Swiss Med Wkly 142：w13624, 2012

8）Adler RA：Update on rare adverse events from osteoporosis therapy and bisphosphonate drug holidays. Endocrinol Metab Clin North Am 50：193-203, 2021

9）Edwards BJ, et al：Bisphosphonates and nonhealing femoral fractures；Analysis of the FDA Adverse Event Reporting System（FAERS）and international safety efforts；A systematic review from the Research on Adverse Drug Events And Reports（RADAR）project. J Bone Joint Surg Am 95：297-307, 2013

10）Black DM, et al：Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383：743-753, 2020

11）Adler RA, et al：Managing osteoporosis in patients on long-term bisphosphonate treatment；Report of a task force of the American society for bone and mineral research. J Bone Miner Res 31：16-35, 2016

Clinical Practice Guideline. J Clin Endocrinol Metab 104：1595-1622, 2019

13）Kendler DL, et al：Denosumab in the treatment of osteoporosis；10 years later；A narrative review. Adv Ther 39：58-74, 2022

14）Reid IR, et al：Drug therapy for osteoporosis in older adults. Lancet 399：1080-1092, 2022

15）Wang M, et al：Bisphosphonate drug holidays；Evidence from clinical trials and real-world studies. JBMR Plus 6：e10629, 2022

16）Diez-Perez A, et al：Treatment failure in osteoporosis. Osteoporos Int 23：2769-2774, 2012